Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | PKLR | P30613 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL762005 | 0.88 | CYP11B1 (0.49) | ALDH1A1POLBARCYP11B1CYP11B2 | |
| SCHEMBL14349339 | 0.87 | PKM (0.43) | POLBPKMNPC1PKLRRAB9A | |
| SCHEMBL13151212 | 0.85 | ALDH1A1 (0.44) | ALDH1A1POLBNPC1RAB9AAR | |
| SCHEMBL14349379 | 0.84 | TDP1 (0.39) | ALDH1A1POLBPKMNPC1PKLR | |
| SCHEMBL24226100 | 0.83 | ALDH1A1 (0.43) | ALDH1A1POLBNPC1RAB9AHRH3 | |
| SCHEMBL14263433 | 0.82 | ALDH1A1 (0.47) | ALDH1A1POLBPKMHRH3L3MBTL1 | |
| SCHEMBL13165269 | 0.82 | PDE3B (0.51) | ALDH1A1POLBPKMKMT2A | |
| SCHEMBL22693082 | 0.81 | ALDH1A1 (0.44) | ALDH1A1POLBARHRH3L3MBTL1 | |
| SCHEMBL25039105 | 0.81 | ALDH1A1 (0.44) | ALDH1A1POLBARHRH3L3MBTL1 | |
| SCHEMBL13165250 | 0.79 | NOTUM (0.60) | ALDH1A1POLBKMT2ANOTUMTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713322-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | CAPELLA THERAPEUTICS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11655224-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2023-05-23 | — | — | US | disclosed |
| US-11649242-B2 | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators | FORMA THERAPEUTICS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230065368-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO PTE. LTD. (SG) | 2023-02-16 | — | — | US | disclosed |
| US-20230025301-A1 | Novel Heterocyclic Derivatives with Cardiomyocyte Proliferation Activity for Treatment of Heart Diseases | TONGJI UNIVERSITY (CN) | 2023-01-26 | — | — | US | disclosed |
| US-20210346356-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. | 2021-11-11 | — | — | US | disclosed |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-11-10 | — | — | US | disclosed |
| US-20200239458-A1 | INHIBITORS OF PROTEIN KINASES | ALEXION PHARMACEUTICALS, INC. | 2020-07-30 | — | — | US | disclosed |
| US-10596172-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-03-24 | — | — | US | disclosed |
| US-20100105665-A1 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100048567-A1 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20090318407-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090318407-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090312318-A1 | THERAPEUTIC COMPOUNDS AND METHODS | GILEAD SCIENCES, INC. | 2009-12-17 | — | — | US | disclosed |
| US-20090286814-A1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-11-19 | — | — | US | disclosed |
| US-20090286814-A1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-11-19 | — | — | US | disclosed |
| EP-1458392-B1 | ACRIDONES AS INHIBITORS OF IMPDH ENZYME | BRISTOL MYERS SQUIBB CO (US) | 2009-09-02 | — | — | EP | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318407-A1 | Inhibitors of protein kinases | SYK, BTK, JAK1 | ALDH1A1 4344/4885POLB 2948/4885PKM 783/4885 |
| US-20100105665-A1 | RENIN INHIBITORS | REN, ACE, AGT | ALDH1A1 947/4885POLB 1491/4885PKM 638/4885 |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | ABCG2, CYP3A43, CYP3A5 | ALDH1A1 684/4885POLB 3726/4885PKM 2625/4885 |
| US-20210346356-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | USP9X, RBX1, USP19 | ALDH1A1 2583/4885POLB 1198/4885PKM 3071/4885 |
| US-20230025301-A1 | Novel Heterocyclic Derivatives with Cardiomyocyte Proliferation Activity for Treatment of Heart Diseases | TNNI3, TNNT2, MKI67 | ALDH1A1 1360/4885POLB 2280/4885PKM 278/4885 |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | PFKFB3, PFKFB4, PFKFB1 | ALDH1A1 1943/4885POLB 1101/4885PKM 29/4885 |
| US-11655224-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | DPP4, DPP7, DPEP1 | ALDH1A1 78/4885POLB 3144/4885PKM 2986/4885 |
| US-20230065368-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | USP9X, USP19, USP39 | ALDH1A1 1794/4885POLB 2574/4885PKM 3873/4885 |
| US-20090312318-A1 | THERAPEUTIC COMPOUNDS AND METHODS | SERPINB1, ABCC1, SERPINB6 | ALDH1A1 1840/4885POLB 2109/4885PKM 1396/4885 |
| US-20200239458-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK1 | ALDH1A1 4344/4885POLB 2948/4885PKM 783/4885 |
| US-20090286814-A1 | HCV PROTEASE INHIBITORS | HAVCR2, SPINT2, RNASE1 | ALDH1A1 982/4885POLB 2873/4885PKM 3156/4885 |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | ABL1, DCK, ERBB2 | ALDH1A1 1989/4885POLB 1267/4885PKM 695/4885 |
| US-11713322-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | ERBB2, ERBB4, ERBB3 | ALDH1A1 1322/4885POLB 1676/4885PKM 981/4885 |
| US-20100048567-A1 | Inhibitors of syk and JAK protein kinases | SYK, BTK, JAK1 | ALDH1A1 3700/4885POLB 3100/4885PKM 602/4885 |
| US-11649242-B2 | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators | PDK1, PKM, PKLR | ALDH1A1 3741/4885POLB 1821/4885PKM 2/4885 |
| US-10596172-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | ALDH1A1 2583/4885POLB 1191/4885PKM 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.